All In Biotech

Drug Trial Radar · NCT07618247

Single Ascending Doses (SAD) and Multiple Ascending Doses(MAD) Study of IG001119 in Healthy Adult Participants

A Randomized, Double-Blinded, Placebo-Controlled, Single- and Multiple-Ascending-Dose Phase Ⅰ Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of IG001119 in Healthy Participants

Last checked: Nov 20, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

96

Planned (sponsor's estimate)

Start

Jul 7, 2026

Primary completion

Apr 30, 2027

Study completion May 30, 2027

Sponsor

Lead sponsor
Iongen Therapeutics Co., Ltd.Industry
Sponsor type
Industry
First posted
Jun 1, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of IG001119 in Healthy Participants

Conditions

  • Pain

Interventions

  • PlaceboDrug

    Tablets for oral administration.

  • IG001119Drug

    Tablets for oral administration.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The incidence and severity of adverse events (AEs)Time frame: Up to 29 days

Locations

2 sites in 2 countries. Site status is shown where the registry gives one.

  • CMAX

    Adelaide, South Australia, Australia · Recruiting

  • New Zealand Clinical Research

    Christchurch, Canterbury, New Zealand · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.